Tinubu, Pate Reforms Push Pharma Profits to ₦14.8bn

Pharmaceutical manufacturers in Nigeria have recorded their highest profits in over a decade, with combined earnings of listed firms rising sharply to ₦14.8 billion in 2025, buoyed by policy reforms introduced under the administration of Bola Ahmed Tinubu and sectoral changes led by the Coordinating Minister of Health and Social Welfare, Muhammad Ali Pate.

Industry data shows that profits of major pharmaceutical companies more than doubled from ₦6.5 billion in 2024 to ₦14.8 billion in 2025, reflecting a significant turnaround for a sector that previously struggled with foreign exchange volatility, rising import costs and declining margins.

Key players including Neimeth International Pharmaceuticals, May & Baker Nigeria Plc and Fidson Healthcare Plc were among the firms that benefited from the reforms, posting stronger earnings after years of financial pressure.

Analysts attribute the improved performance largely to a combination of government incentives, forex stability and new financing frameworks designed to strengthen domestic manufacturing.

Central to the transformation is the government-backed Presidential Initiative to Unlock Healthcare Value Chains (PVAC), which introduced import duty and tax waivers on pharmaceutical raw materials. The policy significantly lowered the cost of production for local manufacturers and improved their competitiveness against imported medicines.

Under the initiative, pharmaceutical companies gained easier access to essential raw materials at reduced costs, allowing them to expand production and stabilize supply chains that were previously disrupted by foreign exchange shortages.

Another major factor behind the industry’s recovery is improved stability in the foreign exchange market. With the naira experiencing less volatility compared with previous years, pharmaceutical firms have been able to plan procurement cycles more efficiently and reduce losses caused by exchange rate fluctuations.

Industry executives say the more predictable FX environment has enabled companies to manage costs better and protect profit margins, reversing the margin compression that had plagued the sector.

The government has also supported the industry through innovative financing structures designed to de-risk investments in local drug manufacturing. Under reforms supervised by the health ministry, new guarantor financing mechanisms were introduced to support pharmaceutical production.

The financing programme includes a €1 billion facility from the European Investment Bank and an additional $1 billion from African Export-Import Bank aimed at boosting local production of medicines and health products.

Officials say the funds are expected to expand production capacity, encourage new investments and strengthen Nigeria’s pharmaceutical value chain.

The improved operating environment has already triggered expansion across the industry. Sector observers estimate that more than 30 percent of new pharmaceutical manufacturing firms have emerged as a result of the improved policy framework and investment climate.

READ ALSO: Rising Pump Prices Stoke Inflation Alarm

Government officials say the reforms are part of a broader strategy to reduce Nigeria’s dependence on imported medicines and build a resilient healthcare manufacturing sector capable of serving both domestic and regional markets.

The tax waivers supporting the sector are scheduled to remain in place until March 2027, giving manufacturers time to expand capacity, modernize production facilities and invest in research and development.

Industry stakeholders believe the sustained policy support could transform Nigeria into a major pharmaceutical production hub in West Africa.

With the combination of fiscal incentives, improved foreign exchange conditions and expanded financing opportunities, analysts say the sector is entering a new growth phase that could redefine the country’s healthcare manufacturing landscape in the coming years.